rethinkPeptides Search
Menu
Study breakdown

Brain Natriuretic Peptide Shows Therapeutic Potential for Acute Pulmonary Embolism

evidence
The takeaway

BNP reduced pulmonary artery resistance in a PE rat model and improved clinical outcomes in patients with intermediate-high-risk PE through NPRC-mediated reduction of endothelial oxidative stress.

Biomarker becomes therapy

BNP, traditionally measured as a diagnostic heart failure biomarker, directly treats pulmonary embolism by relaxing lung blood vessels

What the researchers found

BNP reduced right ventricular pressure and improved survival in PE rats, and improved clinical outcomes in intermediate-high-risk PE patients, through NPRC-mediated NADPH oxidase 2 reduction and decreased myosin light chain phosphorylation in PA smooth muscle.

Why it matters

PE is the third leading cause of cardiovascular death. BNP could provide a new treatment option for intermediate-high-risk patients who are too unstable for standard therapy alone.

How the study worked

Rat PE model with autologous thrombi, BNP dose optimization, mechanistic studies (oxidative stress, NPRC signaling), and observational comparison of PE patients receiving BNP + anticoagulation vs anticoagulation alone.

What this study cannot tell us

Small clinical observation (not randomized). Rat PE model may not fully replicate human PE. BNP dosing optimization for PE needs further study. NPRC-mediated mechanism needs human validation.

How to read the evidence

Preclinical mechanistic study with supportive clinical observation. Novel therapeutic concept needing randomized trial confirmation.

When this study was published

Published in 2025.

The bigger picture

This repositions BNP from a diagnostic biomarker to a therapeutic agent, demonstrating that natriuretic peptides have direct vascular therapeutic effects beyond their diagnostic utility.

Questions still open

  • Would a randomized trial of BNP in intermediate-high-risk PE confirm these benefits?
  • What is the optimal BNP dose and infusion duration for PE treatment?
  • Could synthetic BNP analogs with longer half-lives be more practical?

Common questions

What is BNP and how can it treat pulmonary embolism?
BNP (brain natriuretic peptide) is a natural hormone produced by the heart. While usually measured as a diagnostic test, this study shows it can actively treat PE by relaxing constricted lung blood vessels and reducing oxidative damage.
Is this treatment available now?
BNP (as nesiritide) is approved for heart failure but not yet for PE. This study provides the rationale for clinical trials testing BNP as an additional PE treatment.

Read the original research

Brain natriuretic peptide protects against acute pulmonary embolism-induced pulmonary vasoconstriction through natriuretic peptide receptor C.

Basic research in cardiology

Citation

Gao, Yizhuo; Liu, Shiqi; Gu, Zhichun; Wei, Xuejiao; Han, Xue; Wei, Shibo; Yang, Jing; Liu, Yuchen; Jia, Dong. (2026). Brain natriuretic peptide protects against acute pulmonary embolism-induced pulmonary vasoconstriction through natriuretic peptide receptor C.. Basic research in cardiology. https://doi.org/10.1007/s00395-026-01166-9